Cargando…

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management

Detalles Bibliográficos
Autores principales:	Lopez, Salvatore, Zeybek, Burak, Santin, Alessandro D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291176/ https://www.ncbi.nlm.nih.gov/pubmed/30613348 http://dx.doi.org/10.18632/oncotarget.26413

Ejemplares similares

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma
por: Ren, Yulan, et al.
Publicado: (2011)

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Improved survival of patients with hypermutation in uterine serous carcinoma
por: Santin, Alessandro D., et al.
Publicado: (2015)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
por: ElSahwi, Karim S., et al.
Publicado: (2011)

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

Stage III uterine serous carcinoma: modern trends in multimodality treatment
por: Li, Jessie Y., et al.
Publicado: (2020)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Uterine Immunity and Microbiota: A Shifting Paradigm
por: Agostinis, Chiara, et al.
Publicado: (2019)

Combined modality therapy in the adjuvant treatment of uterine serous carcinoma
por: Block, Alec M., et al.
Publicado: (2016)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
por: Santin, A D, et al.
Publicado: (2005)

Staghorn calculi: Understanding the paradigm shift in management
por: Desai, Mahesh, et al.
Publicado: (2020)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Pathogenesis and Clinical Management of Uterine Serous Carcinoma
por: Zhang, Li, et al.
Publicado: (2020)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

A paradigm shift in pulmonary arterial hypertension management
por: Rubin, Lewis J., et al.
Publicado: (2013)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
por: Santin, A D, et al.
Publicado: (2004)

Advances in glaucoma surgery: Paradigm shift in management
por: Pathak-Ray, Vanita
Publicado: (2016)

Expression of HER-2/neu in Oral Squamous Cell Carcinoma
por: Mirza, Sana, et al.
Publicado: (2020)

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
por: Han, Chanhee, et al.
Publicado: (2018)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Medical management of thyroid eye disease – A paradigm shift
por: Honavar, Santosh G
Publicado: (2020)

Paradigm Shift in Life Sciences
por: Kim, Kisoon
Publicado: (2018)

Paradigm Shift in Spinal Surgery
por: Kim, Hyeun-Sung, et al.
Publicado: (2023)

Paradigm shift – For effective management of diabetic retinopathy and glaucoma
por: Ravilla, Thulasiraj
Publicado: (2018)

Comprehensive pelvic and paraaortic lymphadenectomy in patients with apparently early stage uterine serous carcinoma – an anachronism?
por: Emons, Günter
Publicado: (2020)

The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas
por: Ansari, J, et al.
Publicado: (2011)

Mortality and Glycemic Targets in the Intensive Care Unit: Another Paradigm Shift?
por: Cefalu, William T.
Publicado: (2009)

High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
por: Damast, Shari, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n3537vso7giflfctk4o8gst3hf